Sign In
Buy FDMT
$9.53
+0.260 (+2.80%)
At Close: Jun 03, 2026
4DMT to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 27'th May 2026
EMERYVILLE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th
4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
06:30pm, Friday, 22'nd May 2026
4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
08:03pm, Saturday, 16'th May 2026
4D Molecular Therapeutics NASDAQ: FDMT executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage devel
4DMT Announces New Employment Inducement Grants
04:05pm, Friday, 15'th May 2026
EMERYVILLE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th
4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
07:40pm, Wednesday, 13'th May 2026
4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
08:11pm, Thursday, 07'th May 2026
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to a loss of $0.86 per share a year ago.
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
04:05pm, Thursday, 07'th May 2026
EMERYVILLE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th
4DMT to Participate in Upcoming Investor Conferences
08:00am, Monday, 04'th May 2026
EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th
4DMT Announces New Employment Inducement Grants
04:05pm, Friday, 17'th Apr 2026
EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted
4D Molecular Therapeutics (NASDAQ:FDMT) versus TransCode Therapeutics (NASDAQ:RNAZ) Head-To-Head Contrast
01:33am, Friday, 03'rd Apr 2026
TransCode Therapeutics (NASDAQ: RNAZ - Get Free Report) and 4D Molecular Therapeutics (NASDAQ: FDMT - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will co
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A.
03:33am, Tuesday, 31'st Mar 2026
Assenagon Asset Management S.A. decreased its position in 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) by 55.4% in the fourth quarter, according to its most recent 13F filing with the Securities and
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up Following Analyst Upgrade
01:32am, Friday, 20'th Mar 2026
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report)'s stock price gapped up before the market opened on Thursday after Royal Bank Of Canada raised their price target on the stock from $32
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
06:25pm, Wednesday, 18'th Mar 2026
4D Molecular Therapeutics, Inc. (FDMT) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of a loss of $0.53 per share. This compares to a loss of $0.9 per share
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
04:05pm, Wednesday, 18'th Mar 2026
EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted
4DMT to Participate in Upcoming Investor Meetings
08:00am, Monday, 16'th Mar 2026
EMERYVILLE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted
